A Phase 3 interventional study of Placebo Oral Tablet and Roluperidone 32 mg in Negative Symptoms of Schizophrenia, sponsored by Minerva Neurosciences. Completed at 39 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by Minerva Neurosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Schizophrenia with a site in Ukraine — 1 open to participants now, 1 under way, 1 of them phase 3. Schizophrenia · Ukraine.
Among the 93 studies in Schizophrenia with a site in Ukraine, this one is the 35th largest by enrollment of the 92 interventional ones that give a count, is one of 9 that started in 2017, is one of 68 in phase 3, and was the 73rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →1 of the 93 studies in Schizophrenia with a site in Ukraine is open now. Recruiting first, the newest first:
Gedeon Richter Plc. · Sites in Ukraine, United States, Bulgaria and 5 more countries
Ages 13–17
A study can be open while its sites in Ukraine have not opened yet or have stopped. Only those recruiting at a site in Ukraine →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 22 · Phase 3 69 · Phase 4 2
First in 2004; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 515 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 446 across the 92 interventional studies, 3,064 across the 1 observational. Of the 92 that completed or were terminated, 72 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
93 of 93 have an industry lead sponsor. The 10 most frequent:
Minerva Neurosciences is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Minerva Neurosciences has 4 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
1 of the studies in Schizophrenia with a site in Ukraine that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03817502Phase 3Gedeon Richter Plc.Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 93 studies in Schizophrenia with a site in Ukraine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
MIN-101C07 is a multicenter, multinational, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of roluperidone in adult schizophrenia patients.The primary objective is to evaluate the efficacy of 2 fixed doses of roluperidone compared to placebo in improving the negative symptoms of schizophrenia over 12 weeks of double-blind treatment as measured by the change in Positive and Negative Syndrome Scale (PANSS) Marder negative symptoms factor score (NSFS) over 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roluperidone 64 mg for entire study
Drug: Roluperidone 64 mg
Roluperidone mg for entire study
Drug: Roluperidone 32 mg
Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension
Drug: Placebo Oral Tablet · Drug: Roluperidone 64 mg
Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension
Drug: Placebo Oral Tablet · Drug: Roluperidone 32 mg
Placebo administered as a single dose once daily
Roluperidone administered as a single dose once daily
Roluperidone administered as a single dose once daily
Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS)
The Marder negative symptoms factor score (NSFS) derived from the complete Positive and Negative Syndrome Scale (PANSS) has been the most frequently used scale in schizophrenia clinical studies focusing on negative symptoms The PANSS measures comprehensive psychiatric symptoms, including positive, negative, and general symptoms. The full PANSS rates the patient on 30 different symptoms from 1 (absent) to 7 (extreme) based on an interview as well as reports of family members or primary care hospital workers. The NSFS consists of the sum of the negative symptom PANSS items N1, N2, N3, N4, N6, G7, and G16 (minimum score = 7; maximum score = 49). Higher scores indicate more severe symptoms.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline to Week 12 in Personal and Social Performance (PSP)
The PSP scale is a validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (eg, work and study), personal and social relationships, self care, and disturbing and aggressive behaviors. It is a reliable, quick measure of personal and social functioning of patients with schizophrenia and can be used on patients in the acute and stable stage. PSP is a 100-point scale, divided into 10 equal intervals. The score is based on the assessment of a patient's performance in the 4 domains. Lower scores of 1 to 30 reflected poor functioning that the patient required intensive support or supervision; scores of 31 to 60 reflected varying degrees of disability; and scores of 71 to 100 reflected absence of disability or only mild difficulties.
Time frame: Baseline, Week 4, Week 8, and Week 12
Change From Baseline to Week 12 in Clinical Global Impression of Severity (CGI-S)
The Clinical Global Impression of Severity (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Number of Participants With Potentially Clinically Significant Laboratory Values (Whole Study Period; Safety Population)
Laboratory abnormalities were determined using pre-defined normal ranges. Clinical laboratory values were considered potentially clinically significant (PCS) for select parameters of hematology, chemistry, and urinalysis. The number and percentage of patients experiencing PCS laboratory abnormalities post-baseline were summarized by treatment group.
Time frame: Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")
Number of Participants With Potentially Clinically Significant ECG Parameters (Whole Study Period; Safety Population)
QTcF values were tabulated for their absolute values and tabulated relative to Baseline measurements in order to detect individual QTcF changes. The number and percentage of patients who met criteria for potentially clinically significant (PCS) values were summarized.
Time frame: Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")
Number of Participants With Potentially Clinically Significant Vital Signs (Whole Study Period; Safety Population)
The number and percentage of patients with any potentially clinically significant (PCS) vital sign (systolic blood pressure, diastolic blood pressure, heart rate/pulse rate, temperature) occurring post-Baseline were summarized.
Time frame: Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period")
Safety Assessment - Abnormal Involuntary Movement Scale (AIMS)
AIMS is rating scale that was designed to measure tardive dyskinesia (TD). For the scoring, the AIMS scale has 14 items. The first 10 items (under categories of Facial and Oral Movements, Extremity Movements, Trunk Movements, and Global Judgements) are rated from 0 (none) to 4 (severe); the remaining 4 items (Dental Status) are rated "yes" and "no" and not counted. The analysis is limited to items 1 to 10, with each rated from 0 to 4. The total score is the sum of all 10 items and with values ranging from 0 to 40. For the analysis, the observed composite movement (total) score will be summarized by treatment group and study visit. Higher scores imply worse outcome.
Time frame: Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.
Safety Assessments - Barnes Akathisia Rations Scale (BARS)
The BARS is a multiple-choice questionnaire that clinicians used to provide an assessment of akathisia. The BARS scale has 3 items that are rated from 0 (absence/no distress) to 3 (most severe). The BARS rating scale is scored by summing the scales for Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related to Restlessness yielding a total score ranging from 0 to 9. The Total score, which has a possible range from 0-9, is reported. Higher scores imply worse outcome.
Time frame: Baseline, Week 1, Week 2, Week 3, Week 4, Week 8, and Week 12
Safety Assessments -Simpson-Angus Scale (S-AS) Score
The S-AS is an established reliable and valid rating scale that measures drug-induced extrapyramidal syndromes using 10 items rated from 0 = not present to 4 = extremely severe. It consisted of 1 item measuring gait (hypokinesia), 6 items measuring rigidity (arm dropping, shoulder shacking, elbow rigidity, wrist rigidity, leg pendulousness, and head dropping) and 3 items measuring glabella tap, tremor, and salivation. As such, the range of scores was 0 to 40, with increased scores indicating increased severity.
Time frame: Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 13, 14, 15, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.
Safety Assessments - Sheehan Suicidality Tracking Scale (STS) Total Score
Sheehan Suicidality Tracking Scale (STS) is a prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Scoring: Each item is scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely). Data from the STS can be analyzed as individual item scores, a subscore for suicidal ideation (sum of scores from items 2, 3, and 4, plus score from item 5 if ≤ 1), a subscore for suicidal behavior (sum of scores from items 6, 7, and 8, plus score from item 5 if \> 1) and the total scale score (calculated by add scores from Questions 1a (only if 1b is coded YES), + 2 through 11 + \[the highest of 12 or any row of 16\] + \[the highest of 14 or any row of 15\] + 17 + 20. Analysis: The total scale score will be summarized by treatment group and study visit. Complete data will be presented in patient data listings by treatment group and visit. The total score is the sum of all 16 questions and with values ranging from 0 to 64. Higher scores imply worse outcome.
Time frame: Study Baseline Day -1, Active Baseline last assessment on placebo at Week 12, as appropriate, Weeks 13, 14, 15, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 54. Active Baseline=last assessment before receiving Roluperidone.
| Milestone | Placebo in Double Blind to Roluperidone 32 mg in Open Label | Placebo in Double Blind to Roluperidone 64 mg in Open Label | Roluperidone 32 mg at Any Time | Roluperidone 64 mg at Any Time | Placebo in Double Blind |
|---|---|---|---|---|---|
| Started | 0 | 0 | 170 | 171 | 172 |
| Completed | 0 | 0 | 107 | 104 | 122 |
| Not completed | 0 | 0 | 63 | 67 | 50 |
| Milestone | Placebo in Double Blind to Roluperidone 32 mg in Open Label | Placebo in Double Blind to Roluperidone 64 mg in Open Label | Roluperidone 32 mg at Any Time | Roluperidone 64 mg at Any Time | Placebo in Double Blind |
|---|---|---|---|---|---|
| Started | 59 | 63 | 107 | 104 | 0 |
| Completed | 35 | 36 | 72 | 59 | 0 |
| Not completed | 24 | 27 | 35 | 45 | 0 |
| Milestone | Placebo in Double Blind to Roluperidone 32 mg in Open Label | Placebo in Double Blind to Roluperidone 64 mg in Open Label | Roluperidone 32 mg at Any Time | Roluperidone 64 mg at Any Time | Placebo in Double Blind |
|---|---|---|---|---|---|
| Started | 0 | 0 | 229 | 234 | 50 |
| Completed | 0 | 0 | 107 | 95 | 0 |
| Not completed | 0 | 0 | 122 | 139 | 50 |
The Marder negative symptoms factor score (NSFS) derived from the complete Positive and Negative Syndrome Scale (PANSS) has been the most frequently used scale in schizophrenia clinical studies focusing on negative symptoms The PANSS measures comprehensive psychiatric symptoms, including positive, negative, and general symptoms. The full PANSS rates the patient on 30 different symptoms from 1 (absent) to 7 (extreme) based on an interview as well as reports of family members or primary care hospital workers. The NSFS consists of the sum of the negative symptom PANSS items N1, N2, N3, N4, N6, G7, and G16 (minimum score = 7; maximum score = 49). Higher scores indicate more severe symptoms.
| score on a scale | Roluperidone 32 mg | Roluperidone 64 mg | Placebo |
|---|---|---|---|
| Baseline | 25.2 ± 3.43 | 25.3 ± 3.26 | 24.3 ± 3.01 |
| Change from Baseline to Week 2 | -1.2 ± 2.22 | -1.7 ± 2.47 | -1.2 ± 2.46 |
| Change from Baseline to Week 4 | -2.6 ± 2.57 | -2.8 ± 2.92 | -1.8 ± 2.99 |
| Change from Baseline to Week 8 | -3.4 ± 3.49 | -3.8 ± 3.32 | -2.8 ± 3.44 |
| Change from Baseline to Week 12 | -3.7 ± 3.20 | -4.5 ± 3.85 | -3.5 ± 3.97 |
The PSP scale is a validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (eg, work and study), personal and social relationships, self care, and disturbing and aggressive behaviors. It is a reliable, quick measure of personal and social functioning of patients with schizophrenia and can be used on patients in the acute and stable stage. PSP is a 100-point scale, divided into 10 equal intervals. The score is based on the assessment of a patient's performance in the 4 domains. Lower scores of 1 to 30 reflected poor functioning that the patient required intensive support or supervision; scores of 31 to 60 reflected varying degrees of disability; and scores of 71 to 100 reflected absence of disability or only mild difficulties.
| score on a scale | Roluperidone 32 mg | Roluperidone 64 mg | Placebo |
|---|---|---|---|
| Baseline | 52.7 ± 12.28 | 53.0 ± 10.60 | 52.9 ± 11.02 |
| Change from Baseline to Week 4 | 1.6 ± 6.10 | 3.2 ± 6.30 | 1.2 ± 5.92 |
| Change from Baseline to Week 8 | 3.6 ± 7.09 | 5.0 ± 6.76 | 3.1 ± 7.82 |
| hange from Baseline to Week 12 | 4.6 ± 7.98 | 6.2 ± 8.67 | 4.2 ± 7.48 |
The Clinical Global Impression of Severity (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients
| score on a scale | Roluperidone 32 mg | Roluperidone 64 mg | Placebo |
|---|---|---|---|
| Baseline | 4.0 ± 0.62 | 4.0 ± 0.61 | 4.0 ± 0.58 |
| Change from Baseline to Week 2 | -0.1 ± 0.44 | -0.1 ± 0.54 | -0.1 ± 0.50 |
| Change from Baseline to Week 4 | -0.2 ± 0.49 | -0.3 ± 0.55 | -0.1 ± 0.44 |
| Change from Baseline to Week 8 | -0.3 ± 0.61 | -0.4 ± 0.68 | -0.2 ± 0.60 |
| Change from Baseline to Week 12 | -0.4 ± 0.68 | -0.4 ± 0.67 | -0.3 ± 0.63 |
Laboratory abnormalities were determined using pre-defined normal ranges. Clinical laboratory values were considered potentially clinically significant (PCS) for select parameters of hematology, chemistry, and urinalysis. The number and percentage of patients experiencing PCS laboratory abnormalities post-baseline were summarized by treatment group.
| Participants | Roluperidone 32 mg | Roluperidone 64 mg | Placebo |
|---|---|---|---|
| Low potentially clinically significant laboratory values | 43 | 37 | 18 |
| High potentially clinically significant laboratory values | 51 | 48 | 21 |
QTcF values were tabulated for their absolute values and tabulated relative to Baseline measurements in order to detect individual QTcF changes. The number and percentage of patients who met criteria for potentially clinically significant (PCS) values were summarized.
| Participants | Roluperidone 32 mg | Roluperidone 64 mg | Placebo |
|---|---|---|---|
| Highest absolute QTcF interval > 450 -480 msec | 10 | 24 | 1 |
| Highest absolute QTcF interval > 480 -500 msec | 0 | 2 | 0 |
| Highest absolute QTcF interval > 500 msec | 0 | 2 | 0 |
The number and percentage of patients with any potentially clinically significant (PCS) vital sign (systolic blood pressure, diastolic blood pressure, heart rate/pulse rate, temperature) occurring post-Baseline were summarized.
| Participants | Roluperidone 32 mg | Roluperidone 64 mg | Placebo |
|---|---|---|---|
| Number of Participants With Potentially Clinically Significant Vital Signs (Whole Study Period; Safety Population) | 37 | 28 | 20 |
AIMS is rating scale that was designed to measure tardive dyskinesia (TD). For the scoring, the AIMS scale has 14 items. The first 10 items (under categories of Facial and Oral Movements, Extremity Movements, Trunk Movements, and Global Judgements) are rated from 0 (none) to 4 (severe); the remaining 4 items (Dental Status) are rated "yes" and "no" and not counted. The analysis is limited to items 1 to 10, with each rated from 0 to 4. The total score is the sum of all 10 items and with values ranging from 0 to 40. For the analysis, the observed composite movement (total) score will be summarized by treatment group and study visit. Higher scores imply worse outcome.
| score on a scale | Placebo in DB to Roluperidone 32 mg in OL Extension | Placebo in DB to Roluperidone 64 mg in OL Extension | Roluperidone 32 mg at Any Time | Roluperidone 64 mg at Any Time |
|---|---|---|---|---|
| Study Baseline | 0.2 ± 1.23 | 0.1 ± 0.62 | 0.4 ± 1.40 | 0.3 ± 1.04 |
| Active Baseline | 0.2 ± 1.45 | 0.1 ± 0.52 | 0.4 ± 1.20 | 0.3 ± 1.15 |
| Week 16 | 0.2 ± 0.88 | 0.1 ± 0.56 | 0.5 ± 1.38 | 0.2 ± 1.18 |
| Week 20 | 0.1 ± 0.50 | 0.1 ± 0.56 | 0.4 ± 1.60 | 0.2 ± 1.06 |
| Week 24 | 0.1 ± 0.51 | 0.1 ± 0.57 | 0.4 ± 1.31 | 0.2 ± 1.37 |
| Week 28 | 0.1 ± 0.52 | 0.1 ± 0.59 | 0.4 ± 1.30 | 0.2 ± 1.38 |
| Week 32 | 0.1 ± 0.55 | 0.1 ± 0.60 | 0.4 ± 1.19 | 0.2 ± 1.45 |
| Week 36 | 0.1 ± 0.69 | 0.1 ± 0.63 | 0.4 ± 1.29 | 0.2 ± 1.48 |
| Week 40 | 0.1 ± 0.56 | 0.1 ± 0.63 | 0.3 ± 1.06 | 0.3 ± 1.53 |
| Week 44 | 0.1 ± 0.33 | 0.0 ± 0.16 | 0.3 ± 1.17 | 0.1 ± 0.40 |
| Week 48 | 0.1 ± 0.36 | 0.2 ± 0.59 | 0.4 ± 1.38 | 0.3 ± 1.57 |
| Week 52 | 0.1 ± 0.33 | 0.0 ± 0.17 | 0.3 ± 1.31 | 0.3 ± 1.63 |
| Week 54 | 0.1 ± 0.34 | 0.0 ± 0.17 | 0.5 ± 1.55 | 0.3 ± 1.63 |
The BARS is a multiple-choice questionnaire that clinicians used to provide an assessment of akathisia. The BARS scale has 3 items that are rated from 0 (absence/no distress) to 3 (most severe). The BARS rating scale is scored by summing the scales for Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related to Restlessness yielding a total score ranging from 0 to 9. The Total score, which has a possible range from 0-9, is reported. Higher scores imply worse outcome.
| score on a scale | Roluperidone 32 mg | Roluperidone 64 mg | Placebo |
|---|---|---|---|
| Baseline | 0.1 ± 0.39 | 0.1 ± 0.42 | 0.1 ± 0.39 |
| Week 1 | 0.1 ± 0.49 | 0.1 ± 0.39 | 0.1 ± 0.34 |
| Week 2 | 0.2 ± 0.55 | 0.1 ± 0.47 | 0.1 ± 0.41 |
| Week 3 | 0.1 ± 0.52 | 0.1 ± 0.43 | 0.1 ± 0.32 |
| Week 4 | 0.1 ± 0.41 | 0.1 ± 0.41 | 0.1 ± 0.32 |
| Week 8 | 0.1 ± 0.40 | 0.1 ± 0.44 | 0.0 ± 0.27 |
| Week 12 | 0.1 ± 0.46 | 0.1 ± 0.37 | 0.0 ± 0.22 |
The S-AS is an established reliable and valid rating scale that measures drug-induced extrapyramidal syndromes using 10 items rated from 0 = not present to 4 = extremely severe. It consisted of 1 item measuring gait (hypokinesia), 6 items measuring rigidity (arm dropping, shoulder shacking, elbow rigidity, wrist rigidity, leg pendulousness, and head dropping) and 3 items measuring glabella tap, tremor, and salivation. As such, the range of scores was 0 to 40, with increased scores indicating increased severity.
| score on a scale | Placebo in DB to Roluperidone 32 mg in OL Extension | Placebo in DB to Roluperidone 64 mg in OL Extension | Roluperidone 32 mg at Any Time | Roluperidone 64 mg at Any Time |
|---|---|---|---|---|
| Study Baseline | 0.4 ± 0.80 | 0.5 ± 1.25 | 0.8 ± 2.18 | 0.6 ± 1.53 |
| Active Baseline | 0.3 ± 0.83 | 0.1 ± 0.48 | 0.8 ± 2.10 | 0.5 ± 1.44 |
| Week 13 | 0.2 ± 0.63 | 0.2 ± 0.60 | 0.8 ± 1.84 | 0.3 ± 1.04 |
| Week 14 | 0.3 ± 0.81 | 0.2 ± 0.64 | 0.7 ± 1.77 | 0.4 ± 1.56 |
| Week 15 | 0.2 ± 0.48 | 0.2 ± 0.64 | 0.7 ± 1.74 | 0.5 ± 1.61 |
| Week 16 | 0.1 ± 0.34 | 0.1 ± 0.52 | 0.7 ± 1.68 | 0.5 ± 1.63 |
| Week 20 | 0.1 ± 0.33 | 0.1 ± 0.52 | 0.6 ± 1.65 | 0.5 ± 1.64 |
| Week 24 | 0.1 ± 0.40 | 0.1 ± 0.52 | 0.6 ± 1.56 | 0.5 ± 1.73 |
| Week 28 | 0.2 ± 0.48 | 0.1 ± 0.53 | 0.7 ± 1.65 | 0.3 ± 1.66 |
| Week 32 | 0.2 ± 0.49 | 0.1 ± 0.54 | 0.6 ± 1.60 | 0.4 ± 1.68 |
| Week 36 | 0.2 ± 0.50 | 0.1 ± 0.54 | 0.6 ± 1.65 | 0.4 ± 1.70 |
| Week 40 | 0.1 ± 0.30 | 0.1 ± 0.57 | 0.6 ± 1.36 | 0.4 ± 1.69 |
| Week 44 | 0.3 ± 0.77 | 0.1 ± 0.35 | 0.6 ± 1.56 | 0.3 ± 0.82 |
| Week 48 | 0.4 ± 1.52 | 0.1 ± 0.32 | 0.7 ± 1.69 | 0.5 ± 1.79 |
| Week 52 | 0.1 ± 0.35 | 0.1 ± 0.34 | 0.5 ± 1.42 | 0.5 ± 1.84 |
| Week 54 | 0.2 ± 0.49 | 0.2 ± 0.76 | 0.7 ± 1.75 | 0.5 ± 1.83 |
Sheehan Suicidality Tracking Scale (STS) is a prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Scoring: Each item is scored on a 5-point Likert scale from 0 (not at all) to 4 (extremely). Data from the STS can be analyzed as individual item scores, a subscore for suicidal ideation (sum of scores from items 2, 3, and 4, plus score from item 5 if ≤ 1), a subscore for suicidal behavior (sum of scores from items 6, 7, and 8, plus score from item 5 if \> 1) and the total scale score (calculated by add scores from Questions 1a (only if 1b is coded YES), + 2 through 11 + \[the highest of 12 or any row of 16\] + \[the highest of 14 or any row of 15\] + 17 + 20. Analysis: The total scale score will be summarized by treatment group and study visit. Complete data will be presented in patient data listings by treatment group and visit. The total score is the sum of all 16 questions and with values ranging from 0 to 64. Higher scores imply worse outcome.
| score on a scale | Placebo in DB to Roluperidone 32 mg in OL Extension | Placebo in DB to Roluperidone 64 mg in OL Extension | Roluperidone 32 mg at Any Time | Roluperidone 64 mg at Any Time |
|---|---|---|---|---|
| Study Baseline | 0.0 ± 0.00 | 0.0 ± 0.15 | 0.0 ± 0.46 | 0.0 ± 0.08 |
| Active Baseline | 0.0 ± 0.13 | 0.0 ± 0.00 | 0.0 ± 0.00 | 0.0 ± 0.10 |
| Week 12.1 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 12.2 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 13 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.10 |
| Week 14 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 15 | 0.0 ± 0.14 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 16 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.10 | 0.0 ± 0.0 |
| Week 20 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.41 |
| Week 24 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 28 | 0.2 ± 1.44 | 0.0 ± 0.0 | 0.0 ± 0.11 | 0.0 ± 0.0 |
| Week 32 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 36 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.11 | 0.0 ± 0.0 |
| Week 40 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.11 | 0.0 ± 0.0 |
| Week 44 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.22 | 0.0 ± 0.0 |
| Week 48 | 0.1 ± 0.49 | 0.0 ± 0.0 | 0.0 ± 0.12 | 0.0 ± 0.38 |
| Week 52 | 0.0 ± 0.17 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 54 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
Collected over Entire study (which includes double-blind and open-label periods) from Baseline to Week 54 (referred to as the "whole study period").. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo in Double Blind to Roluperidone 32 mg in Open Label | 0/59 (0%) | 1/59 (1.7%) | 2/59 (3.4%) |
| Placebo in Double Blind to Roluperidone 64 mg in Open Label | 1/63 (1.6%) | 5/63 (7.9%) | 7/63 (11.1%) |
| Roluperidone 32 mg at Any Time | 2/229 (0.9%) | 18/229 (7.9%) | 30/229 (13.1%) |
| Roluperidone 64 mg at Any Time | 1/234 (0.4%) | 21/234 (9%) | 39/234 (16.7%) |
| Placebo | 0/172 (0%) | 5/172 (2.9%) | 22/172 (12.8%) |
| Event | Placebo in Double Blind to Roluperidone 32 mg in Open Label | Placebo in Double Blind to Roluperidone 64 mg in Open Label | Roluperidone 32 mg at Any Time | Roluperidone 64 mg at Any Time | Placebo |
|---|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 1/59 | 0/63 | 9/229 | 9/234 | 1/172 |
| Psychotic symptomPsychiatric disorders | 0/59 | 0/63 | 1/229 | 1/234 | 3/172 |
| AnxietyPsychiatric disorders | 0/59 | 1/63 | 1/229 | 2/234 | 0/172 |
| AggressionPsychiatric disorders | 0/59 | 1/63 | 1/229 | 1/234 | 0/172 |
| Sleep DisorderPsychiatric disorders | 0/59 | 1/63 | 1/229 | 1/234 | 1/172 |
| Hallucination, auditoryPsychiatric disorders | 0/59 | 1/63 | 0/229 | 1/234 | 0/172 |
| Pneumonia bacterialInfections and infestations | 0/59 | 1/63 | 0/229 | 1/234 | 0/172 |
| Pneumonia viralInfections and infestations | 0/59 | 1/63 | 0/229 | 1/234 | 0/172 |
| Femur fractureInjury, poisoning and procedural complications | 0/59 | 1/63 | 0/229 | 2/234 | 0/172 |
| ConcussionInjury, poisoning and procedural complications | 0/59 | 1/63 | 0/229 | 1/234 | 0/172 |
| Event | Placebo in Double Blind to Roluperidone 32 mg in Open Label | Placebo in Double Blind to Roluperidone 64 mg in Open Label | Roluperidone 32 mg at Any Time | Roluperidone 64 mg at Any Time | Placebo |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/59 | 5/63 | 8/229 | 15/234 | 4/172 |
| InsomniaPsychiatric disorders | 1/59 | 0/63 | 7/229 | 4/234 | 7/172 |
| SchizophreniaPsychiatric disorders | 0/59 | 0/63 | 6/229 | 5/234 | 5/172 |
| AstheniaGeneral disorders | 0/59 | 1/63 | 3/229 | 6/234 | 4/172 |
| Electrocardiogram QT prolongedInvestigations | 0/59 | 1/63 | 2/229 | 5/234 | 0/172 |
| AgitationPsychiatric disorders | 0/59 | 0/63 | 4/229 | 4/234 | 2/172 |
Patients who Started Treatment.
| Age, Continuous(years) | Roluperidone 64 mg | Roluperidone 32 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 41 ± 9.3 | 41 ± 9.4 | 41 ± 8.7 | 41 ± 9.1 |
| Sex: Female, Male(Participants) | Roluperidone 64 mg | Roluperidone 32 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 68 | 64 | 66 | 198 |
| Male | 103 | 106 | 106 | 315 |
| Ethnicity (NIH/OMB)(Participants) | Roluperidone 64 mg | Roluperidone 32 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 3 | 12 |
| Not Hispanic or Latino | 167 | 165 | 169 | 501 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Roluperidone 64 mg | Roluperidone 32 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 1 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 0 | 3 |
| Black or African American | 18 | 19 | 20 | 57 |
| White | 151 | 147 | 152 | 450 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Roluperidone 64 mg | Roluperidone 32 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 27 | 27 | 27 | 81 |
| Bulgaria | 36 | 37 | 40 | 113 |
| Georgia | 5 | 5 | 2 | 12 |
| Israel | 0 | 4 | 2 | 6 |
| Moldova | 6 | 8 | 5 | 19 |
| Poland | 6 | 5 | 8 | 19 |
| Romania | 19 | 18 | 13 | 50 |
| Ukraine | 72 | 66 | 75 | 213 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in May 2020, 29 months.
Results were first posted in Apr 2023, 2 years 11 months after primary completion. A results delay was requested in Jan 2021.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 29 months is close to that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roluperidone
Minerva Neurosciences